A screening programme for abdominal aortic aneurysms (AAA), integrated into an electronic health record, dramatically reduced the number of unscreened at-risk men by more than 50% within 15 months, according to a Kaiser Permanente study published in the Journal of Vascular Surgery.
Two-year follow-up data have shown that BioMimics 3D, a nitinol stent with unique three-dimensional helical geometry, developed by Veryan Medical, provides an improvement in long-term patency compared to a straight nitinol control stent in patients undergoing femoropopliteal artery intervention for symptomatic peripheral arterial disease.
Interim results from the Chocolate balloon angioplasty registry conducted in the USA demonstrate that use of the TriReme Medical Chocolate percutaneous transluminal angioplasty balloon achieved high rates of treatment success and limb preservation in patients with peripheral arterial disease.
One year results from the prospective, multicentre, randomised, core lab-adjudicated FAIR trial comparing drug-eluting balloon to standard percutaneous transluminal angioplasty for the treatment of superficial femoral artery in-stent restenosis showed positive outcomes for the drug-eluting balloon.
Endologix has announced the US launch of its new Vela proximal endograft system, a clinical solution for endovascular repair in a broad range of aortic neck anatomies. A press release from the company says the Vela system is specifically designed for the treatment of proximal aortic neck anatomies during an endovascular aneurysm repair procedure using the Endologix AFX endovascular AAA System.
InspireMD has announced that its new CGuard carotid embolic protection system has been successfully implanted in recent procedures, including a patient treated during the 17(th) Annual Symposium on Interventional Cardiology & Angiology held in Hamburg, Germany on 1 February 2014.
Interventional News has learned that the UK CAVA trial, a four-way randomised controlled trial of long-term venous access devices for the delivery of chemotherapy (Ports versus tunnelled central lines versus peripherally inserted central catheters) has begun.
Boston Scientific has announced the US launch and first use of the OffRoad re-entry catheter system. The system provides a new option to treat chronic total occlusions in the femoropopliteal arteries.
Results with the fully self-expanding Stanza bioresorbable scaffold in the superficial femoral artery were presented by Andrew Holden, Auckland, New Zealand, at the VEITHsymposium. He also presented initial results with the new, drug-eluting version of the device. In the presentation, Holden, who is director of Interventional Services at Auckland City Hospital and associate professor of Radiology at Auckland University School of Medicine, noted that the advantages of a bioresorbable scaffold for treatment of superficial femoral artery disease include allowing vessel scaffolding while leaving nothing behind, eliminating chronic vessel irritation due to stenting, not having future interventions encumbered by a permanent stent, and also allowing non-invasive imaging with MR angiography.
Hemodyn 2013—The International Vasculab Conference, chaired by Dr Fausto Passariello, was held on 7–9 November 2013 at Accademia Aeronautica di Pozzuoli, Italy.The event was a success with an outstanding attendance and a very interesting scientific programme with important clinical updates on vascular disease. It provided great learning and a huge opportunity for all delegates. The venue was stunning and there was a real buzz of excitement throughout the event.
For the first time, the Charing Cross Symposium announces an open call for two new abstract and poster sessions which will run in parallel to the main programme: the first aimed at all physicians—senior and junior—and the second aimed at vascular scientists, nurses and technologists.
Hypertension is one of the most prevalent diseases in the world and represents a major cardiovascular risk factor. Sympathetic nerves of the renal arteries play an important role in the development of hypertension, and both afferent and efferent nerves are responsible for stimuli that through different mechanisms result in an increase of sympathetic tone.
On 20 December 2013, Endologix announced that it has received investigational device exemption (IDE) approval from the FDA to begin a pivotal clinical trial to evaluate the safety and effectiveness of the Nellix EndoVascular Aneurysm Sealing System (EVAS) for the endovascular repair of infrarenal abdominal aortic aneurysms.
Boehringer Ingelheim has announced results from the RE-COVER II study evaluating dabigatran compared to warfarin in patients diagnosed with acute deep vein thrombosis and/or pulmonary embolism. In this phase III study, published online in the American Heart Association’s journal Circulation, dabigatran met the primary endpoint of non-inferiority to warfarin for recurrent, symptomatic, objectively-confirmed deep vein thrombosis and/or pulmonary embolism and related deaths during six months of treatment.
Intact Vascular announced on 17 December 2013 the start of enrolment in the TOBA-BTK (Tack optimized balloon angioplasty below the knee) study. This multicentre pilot study will gather data supporting the safety and performance of the Tack-It Endovascular System in patients with critical limb ischaemia due to vascular disease below the knee. A previously enrolled and ongoing clinical trial recruited patients with claudication due to vascular disease for the above-the-knee indication.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos